How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

244 results for

Emergency Pediatric Dosing 12-14 kilogram

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

Date : July 2015 Actual Study Completion Date : December 2015 Resource links provided by the National Library of Medicine related topics: available for: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: Prasugrel Participants will be titrated from initial daily dose of 0.08 milligram per kilogram (mg/kg) of orally administered prasugrel monotherapy at randomization to a dose that will achieve a P2Y12 reaction units (PRU) level of 231 to 136, as measured by VerifyNow (...) A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD) A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2013 Clinical Trials

62. Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

). Please remove one or more studies before adding more. Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01049022 Recruitment Status : Completed First Posted : January 14, 2010 Last Update Posted (...) /treatment Experimental: Moxifloxacin (Avelox, BAY12-8039), Cohort 1 Drug: Moxifloxacin (Avelox, BAY12-8039) Single intravenous (IV) infusion of moxifloxacin administered over 60 minutes, at an initial dosage of 5 milligram per kilogram per body weight (mg/kg/BW) with dose escalation to 6 mg/kg in subjects of age 6 years (yrs) to less than or equal to (<=) 14 years. Experimental: Moxifloxacin (Avelox, BAY12-8039), Cohort 2 Drug: Moxifloxacin (Avelox, BAY12-8039) Single IV infusion of moxifloxacin

2010 Clinical Trials

63. Programmatic management of latent tuberculosis infection in the European Union

tests 17 Table 12. Evidence base for the effectiveness of LTBI treatment regimens 19 Table 13. Evidence base for cost-effectiveness of LTBI treatment regimens 19 Table 14. Evidence base for feasibility and acceptability of LTBI treatment regimens 20 Table 15. Evidence base on LTBI screening 22 Table 16. Evidence base - treatment-related interventions for programmatic management of LTBI 24 Table 17. Evidence base for education on programmatic management of LTBI 25 Table 18. Considerations (...) . Implications for public health practice and research 29 5.1 Public health practice 29 5.2 Strengths and limitations 36 5.3 Knowledge gaps 37 6. Next steps 38 References 39 Annexes 44 Tables Table 1. Grading of the evidence of included systematic reviews* 6 Table 1. Evidence base of LTBI risk among clinical risk groups 9 Table 4. Evidence base for LTBI risk among population risk groups 11 Table 5. Evidence base for progression to active TB among population risk groups with LTBI 12 Table 6. Evidence base

2019 European Centre for Disease Prevention and Control - Public Health Guidance

64. Treating Opioid Use Disorder During Pregnancy: Guideline Supplement

-informed Care 12 Integrated Medical Management 12 Harm Reduction During Pregnancy 12 Clinical Recommendations 14 Screening Assessments 14 Prenatal Treatment Considerations 14 Opioid Agonist Treatment 14 Methadone 15 Buprenorphine 16 Buprenorphine/naloxone 16 Slow release oral morphine 17 Injectable opioid agonist treatments 17 Residential treatment 18 Withdrawal management (i.e. detoxification) 18 Naltrexone 19 Intrapartum considerations 20 Postpartum considerations 21 Adjustment of OAT and pain (...) . In the process of gauging the effectiveness of the methadone dose, care must be taken to distinguish between symptoms of opioid withdrawal and pregnancy symptoms. For some pregnant patients on methadone, the acceleration of maternal metabolism in the course of pregnancy may require an increase in daily dose to address emergent withdrawal symptoms and prevent fetal stress, particularly in the second or third trimesters. 4,40 If needed, gradual dose increases can be made by increments of 5 mg to 10 mg. Due

2018 British Columbia Perinatal Health Program

65. Heart Disease and Stroke Statistics

. Physical Inactivity e99 5. Nutrition e119 6. Overweight and Obesity e138 Health Factors and Other Risk Factors 7. High Blood Cholesterol and Other Lipids e161 8. High Blood Pressure e174 9. Diabetes Mellitus e193 10. Metabolic Syndrome e212 11. Kidney Disease e233 12. Sleep e249 Cardiovascular Conditions/Diseases 13. Total Cardiovascular Diseases e257 14. Stroke (Cerebrovascular Disease) e281 15. Congenital Cardiovascular Defects and Kawasaki Disease e327 16. Disorders of Heart Rhythm e346 17. Sudden (...) after myocardial infarction (MI), lower risk of atrial fibrillation, and greater positive psychological functioning (dispositional optimism). Among children, from 1999 to 2000 to 2015 to 2016, prevalence of nonsmoking, ideal total cholesterol, and ideal BP improved. For example, nonsmoking among children aged 12 to 19 years went from 76% to 94%. However, meeting ideal levels for physical activity, body mass index (BMI), and blood glucose did not improve. For example, prevalence of ideal BMI declined

Full Text available with Trip Pro

2019 American Heart Association

66. Amitriptyline

withdrawal from the study as well as those that were life threatening. Best Evidence (you may view more info by clicking 2017 2. Trial of Amitriptyline , Topiramate, and Placebo for Pediatric Migraine. BACKGROUND: Which medication, if any, to use to prevent the headache of pediatric migraine has not been established. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of amitriptyline (1 mg per kilogram of body weight per day), topiramate (2 mg per kilogram per day), and placebo (...) Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Amitriptyline Amitriptyline Aka: Amitriptyline , Elavil (...) Weight gain VIII. Precautions See s Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term " Amitriptyline ." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Cost: Medications

2018 Trip Latest and Greatest

67. Interpregnancy Care

by 6–12 months postpartum and ultimately to achieve a normal body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of 18.5–24.9. Ideally, a woman’s weight should be optimized before she attempts to become pregnant ( ), although the health benefits of postponing pregnancy need to be balanced against reduced fecundity with female aging ( ). Postpregnancy weight retention and gain have been associated with subsequent adverse obstetric consequences (...) . Supplementation should begin at least 3 months before fertilization and continue through the first 12 weeks of pregnancy. A thorough review of all prescription and nonprescription medications and potential teratogens and environmental exposures should be undertaken before the next pregnancy. The responsibility of caring for a medically fragile infant may deter women from accessing interpregnancy care. Novel strategies, such as embedding screening and referral services within pediatric follow-up clinics

2019 American College of Obstetricians and Gynecologists

68. Clinical Practice Guideline: Maintenance Intravenous Fluids in Children

than 28 days old or in the NICU; or adolescents older than 18 years old. Background Phases of Fluid Therapy Recent literature has emerged in which researchers describe the context-dependent use of IVFs, which should be prescribed, ordered, dosed, and delivered like any other drug. – Four distinct physiology-driven time periods exist for children requiring IVFs. The resuscitative phase is the acute presentation window, when IVFs are needed to restore adequate tissue perfusion and prevent or mitigate (...) isotonic IVFs. Methods In April 2016, the American Academy of Pediatrics (AAP) convened a multidisciplinary subcommittee composed of primary care clinicians and experts in the fields of general pediatrics, hospital medicine, emergency medicine, critical care medicine, nephrology, anesthesiology, surgery, and quality improvement. The subcommittee also included a guideline methodologist and/or informatician and an epidemiologist who were skilled in systematic reviews. All panel members declared potential

2019 American Academy of Pediatrics

69. CAR T-cell therapy: a summary of evidence

proved challenging • Most completed studies have used an autologous cell source (i.e. from the patient), but Phase I results are emerging for allogeneic CAR T-cell therapies (e.g. UCART19) 12 CAR T-CELL THERAPY EVIDENCE CHECK_WITH PREFACE FROM NSW HEALTH | SAX INSTITUTE • Phase I trials are exploring strategies to reduce on-target/off-tumour autoreactivity of CAR T-cells towards healthy tissue, such as ‘suicide genes’ and safe dosing strategies • Safety outcomes are listed consistently, but we noted (...) Review questions 8 Summary of methods 8 Evidence grading 9 Key findings 9 Gaps in the evidence 12 Discussion of key findings 12 Implications for Australia 12 Conclusion 13 Background 14 Methods 15 Scope of the review 15 The scope of this Evidence Check was to review and summarise available information to address three research questions: 15 Question 1: What regulatory frameworks are in place, or under consideration, for the delivery of CAR T- cell therapy? 15 Question 2: Where CAR T-cell therapies

2018 Sax Institute Evidence Check

70. Overweight, Obesity and Contraception

Health benefits of implants 11 5.2.5 Practical considerations with implants 11 5.3 Progestogen-only injectable 12 5.3.1 DMPA effectiveness 12 5.3.2 DMPA safety 13 5.3.3 Weight gain with DMPA 14 5.3.4 Health benefits of DMPA 15 5.3.5 Practical considerations with DMPA 15vi Copyright ©Faculty of Sexual & Reproductive Healthcare 2019 FSRH guideline: Overweight, Obesity and Contraception 5.4 Progestogen-only pill (POP) 15 5.4.1 POP effectiveness 15 5.4.2 POP safety 16 5.4.3 Weight gain with POP 17 5.4.4 (...) comparing progestogen-only injectable users and non-users reported that current use did not affect risk of combined CVD, risk of stroke, or MI. Evidence level 2++ Studies relating to effect of progestogen-only injectable use on cardiometabolic markers A prospective, non-randomised study 100 of 14 women examined the effects of DMPA-IM or DMPA-SC on coagulation and inflammatory factors indicative of increased risk of thrombosis. Following four injections (i.e. 12 months of DMPA use), coagulation

2019 Faculty of Sexual & Reproductive Healthcare

71. ACR–ASNR–SPR Practice Parameter for the Performance and Interpretation of Cervicocerebral Computed Tomography Angiography (CTA)

of the subclavian and carotid arteries, the Circle of Willis, and may be extended up to the cranial vertex. In some patients, coverage can extend to include the heart, complete aortic arch, the left 6 / Cervicocerebral CTA PRACTICE PARAMETER atrium, the distal intracranial arteries, and the venous sinuses. In the pediatric population, anatomic coverage should be strictly limited to the vascular segments of interest, and variable mA is important in order to keep the radiation dose as low as possible. Automated (...) C, Bradley D. Effects of automated kilovoltage selection technology on contrast- enhanced pediatric CT and CT angiography. Radiology. 2013;268(2):538-547. 65. Komlosi P, Zhang Y, Leiva-Salinas C, et al. Adaptive statistical iterative reconstruction reduces patient radiation dose in neuroradiology CT studies. Neuroradiology. 2014;56(3):187-193. 66. Singh S, Kalra MK, Shenoy-Bhangle AS, et al. Radiation dose reduction with hybrid iterative reconstruction for pediatric CT. Radiology. 2012;263(2

2019 American Society of Neuroradiology

72. American Society for Parenteral and Enteral Nutrition Clinical Guidelines: The Validity of Body Composition Assessment in Clinical Populations

patients following to Roux‐en‐Y gastric bypass N = 14 women N = 4 men (3 dropout) Age: 42 ± 3 y, mean BMI: 43 ± 5 kg/m 2 MRI Siemens 1.5 T MAGNETOM Avanto Nutriguard‐M Data Input Pearson correlation reported MRI vs FM Nutrigard‐M VF Preoperative: CC = 0.07 PO 6 wk: CC = 0.15 PO 12 wk: CC = 0.13 PO 24 wk: CC = 0.47 MRI vs FM Nutrigard‐M SCFV Preoperative: CC = 0.33 PO 6 wk: CC = 0.74 PO 12 wk: CC = 0.61 PO 24 wk: CC = 0.56 Pérez‐Matute et al, 2013 To validate the data obtained by BIA to measure FM (...) or superior methodology in a healthy population, was excluded. Definitions Human body composition is an established yet still emerging field of science that explores the different distributions of lean mass (LM) versus adipose tissue and their impact on health. Despite advances in this field, human body composition research remains plagued by issues of nomenclature, in that specific compartments are often referred to in a multitude of ways, and these terms may not always be synonymous nor comparable

Full Text available with Trip Pro

2019 American Society for Parenteral and Enteral Nutrition

73. Comparative Effectiveness of Analgesics To Reduce Acute Pain in the Prehospital Setting

: 19527280. 13. Sub-dissociative ketamine for the management of acute pediatric pain. NCT01951963. https://clinicaltrials.gov/ct2/show/NCT01951963 ?term=NCT01951963&rank=1. Accessed 11 March, 2019. 14. Galinski M, Dolveck F, Combes X, et al. Management of severe acute pain in emergency settings: ketamine reduces morphine consumption. Am J Emerg Med. 2007 May;25(4):385-390. PMID: 17499654. 15. Jalili M, Mozaffarpour Noori A, Sedaghat M, Safaie A. Efficacy of intravenous paracetamol versus intravenous (...) of intranasal ketamine vs fentanyl on pain reduction for extremity injuries in children: the PRIME randomized clinical trial. JAMA Pediatr. 2019 Feb;173(2):140-146. PMID: 30592476. 20. Reynolds SL, Bryant KK, Studnek JR, et al. Randomized controlled feasibility trial of intranasal ketamine compared to intranasal fentanyl for analgesia in children with suspected extremity fractures. Acad Emerg Med. 2017 Dec;24(12):1430-1440. PMID: 28926159. 21. Graudins A, Meek R, Egerton-Warburton D, Oakley E. The PICHFORK

2019 Effective Health Care Program (AHRQ)

74. Pharmacologic and Nonpharmacologic Therapies in Adult Patients With Exacerbation of COPD

to severe ECOPD. Titrated oxygen reduces mortality. Future research is required to assess the effectiveness of several emerging nonpharmacologic and dietary treatments. ix Contents Evidence Summary ES-1 Introduction 1 Background 1 Key Questions 3 Methods 4 Literature Search Strategy 4 Search Strategy 4 Inclusion and Exclusion Criteria 5 Study Selection 7 Data Abstraction and Data Management 7 Assessment of the Risk of Bias of Individual Studies 7 Data Synthesis 7 Grading the Strength of Evidence (SOE (...) ) for Major Comparisons and Outcomes 9 Assessing Applicability 10 Peer Review and Public Commentary 10 Results 11 Literature Searches and Evidence Base 11 KQ1. In adult patients with exacerbation of COPD, what are the benefits and harms of systemic corticosteroids and antibiotics compared with placebo or standard care? 11 Key Points-KQ1 11 KQ 1 Results 12 Systemic Antibiotics Versus Placebo or Management Without Systemic Antibiotics 12 Systemic Corticosteroids Versus Placebo or Management Without Systemic

2019 Effective Health Care Program (AHRQ)

75. NeoMedQ: Neonatal medicines

within the monographs 13 4.2.1 Incompatibility and interaction 14 4.3 Standard age terms 14 4.4 Parenteral access management 15 4.5 Evidence base 16 4.5.1 Overarching principles 16 4.5.2 Development process 16 References 17 Appendix A: Standard medication terms and abbreviations 18 Appendix B: Routes of administration and dose forms 19 Acknowledgements 20 List of Tables Table 1. Classifications of medication errors 5 Table 2. Factors contributing to medication errors 6 Table 3. Staff support 7 Table (...) 4. Medication management 8 Table 5. Communication 9 Table 6. Labelling 10 Table 7. Consumables and medical devices 10 Table 8. Consumer education 11 Table 9. Legislation and policy 11 Table 10. Routes of administration 12 Table 11. Fields within the monograph 13 Table 12. Incompatibility and interaction 14 Table 13. Terminology of age 14 Table 14. Principles of access management 15 Queensland Clinical Guideline: Neonatal medicines Refer to online version, destroy printed copies after use Page 5

2019 Queensland Health

76. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy

University of California Los Angeles, Los Angeles, California , MD 10 , § , x Milind Y. Desai Affiliations Cleveland Clinic, Cleveland, Ohio , MD 11 , ¶ , x N.A. Mark Estes Affiliations University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania , MD, FHRS, CCDS 12 , x Wei Hua Affiliations Fu Wai Hospital, Beijing, China , MD, FHRS 13 , # , x Julia H. Indik Affiliations University of Arizona, Sarver Heart Center, Tucson, Arizona , MD, PhD, FHRS 14 , x Jodie Ingles Affiliations Agnes Ginges Centre (...) , Argentina Hospital Español, Bahia Blanca, Argentina , MD 18 , 19 , ‡‡ , x Andrew D. Krahn Affiliations The University of British Columbia, Vancouver, Canada , MD, FHRS 20 , x Mark S. Link Affiliations UT Southwestern Medical Center, Dallas, Texas , MD, FHRS 21 , §§ , x Frank I. Marcus Affiliations University of Arizona, Sarver Heart Center, Tucson, Arizona , MD 14 , x Christopher J. McLeod Affiliations Mayo Clinic, Rochester, Minnesota , MBChB, PhD, FHRS 5 , x Luisa Mestroni Affiliations University

2019 International Society for Heart and Lung Transplantation

77. Registries for Evaluating Patient Outcomes: A User's Guide

many sources, including technologies used by the individual. 12, 13 Registries may play a central role in the learning health system and national health data infrastructure as sources of data that can be used to support population health and clinical decision making, quality improvement, and clinical research. 14 In particular, registries often serve as a bridge between clinical trials and clinical practice by continuing to study the effectiveness of new medical products in a real-world setting (...) ) with the purpose of presenting new, emerging themes related to designing and conducting registries. First published in 2007, the User’s Guide, with translations available in Chinese and Korean, serves as a reference for planning, developing, maintaining, and evaluating registries designed to collect data about patient outcomes. The second (2010) and third (2014) editions incorporated updates to existing topics and included new chapters on methodological and technological advances in registry science. The first

2019 Effective Health Care Program (AHRQ)

78. Clinical Practice Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical Support of Patients Undergoing Bariatric Procedures

, FACE 9 ; Jennifer Seger, MD 10 ; Richard Urman, MD, MBA, CPE 11 ; Stephanie Adams, DOI:10.4158/GL-2019-0406 © 2019 AACE. 2 PhD 12 ; John B. Cleek, MD 13 ; Riccardo Correa, MD, FACE 14 ; M. Kathleen Figaro, MD, MS, FACE 15 ; Karen Flanders, MSN, CNP, CBN 16 ; Jayleen Grams, MD, PhD 17 ; Daniel L. Hurley, MD, FACE 18 ; Shanu Kothari, MD, FACS, FASMBS 19 ; Michael V. Seger, MD, FACS, FASMBS 20 ; Christopher D. Still, DO, FACN, FACP 21 1 Guideline Task Force Chair (AACE); Professor of Medicine, Medical (...) of Medicine, UT Health Science Center, San Antonio, Texas 11 Guideline Task Force Co-Chair (ASA); Associate Professor of Anesthesia, Brigham and Women’s Hospital, Boston, Massachusetts 12 Writer (AACE); AACE Director of Clinical Practice Guidelines Development, Jacksonville, Florida 13 Writer (TOS); Associate Professor, Department of Nutrition Sciences, University of Alabama, Birmingham, Alabama DOI:10.4158/GL-2019-0406 © 2019 AACE. 4 14 Technical Analysis (AACE); Assistant Professor of Medicine

2019 American Association of Clinical Endocrinologists

79. Emicizumab for Hemophilia A with Inhibitors: Effectiveness and Value

to Table of Contents Title/ Trial Sponsor Study Design Comparators Patient Population Primary Outcomes Estimated Completion Date A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors (HAVEN 2) Hoffmann-La Roche NCT02795767 Phase III Single-Arm Open Label Multicenter Estimated Enrollment: 80 1. Emicizumab will be administered subcutaneous weekly dose at 3 milligrams per kilogram per week for 4 weeks, followed by 1.5 mg/kg (...) /week up to 52 weeks. From 12 weeks onwards, the dose can be increased from 1.5 to 2.25 mg/kg/week or from 2.25 to 3.0 mg/kg/week if the participant has developed >/=2 bleeds in 12 weeks from Week 5 or 9, respectively. Inclusion Criteria • Children less than = 40 kilograms at the time of screening • Participants without FVIII inhibitors ( =5 bleeds in the last 24 weeks prior to study entry • Adequate hematologic, hepatic, and renal function Exclusion Criteria • Planned surgery during the study • Use

2018 California Technology Assessment Forum

80. Preschool Multiple-Breath Washout Testing: A Technical Statement

by smaller working groups, merged in the overall draft document by the chair, and all authors provided comment and suggestions for the ?nal document. The methods checklist is presented in Table 3. Background Publications including pediatric MBW testing initially emerged in the 1960s (21, 22), whereas the inclusion of preschool children in studies did not occur until two decades later (23, 24). Initial data collected in the 1980s suggested poor feasibility in preschool children. Using custom-built (...) *, and Felix Ratjen*; on behalf of the ATS Assembly on Pediatrics THIS OFFICIAL TECHNICAL STATEMENT OF THE AMERICAN THORACIC SOCIETY WAS APPROVED DECEMBER 2017. Background: Obstructiveairwaydiseaseisnonuniformlydistributed throughoutthebronchialtree,althoughtheextenttowhichthisoccurscan varyamongconditions.Themultiple-breathwashout(MBW)testoffers importantinsightsintopediatriclungdisease,notavailablethroughspirometry orresistancemeasurements.TheEuropeanRespiratorySociety/American

2018 American Thoracic Society

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>